DOYLESTOWN, Pa. , Jan. 11, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics , Inc. (Nasdaq: APRE ), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, today announced that the first patient was dosed in its

BOSTON , Nov. 09, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics , Inc. (Nasdaq: APRE ), a biopharmaceutical company focused on developing and commercializing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways today reported financial results for the three

BOSTON , Sept. 22, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics , Inc. (Nasdaq: APRE ), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, today announced that the abstract titled “ATRN-W1051, a novel

BOSTON , Sept. 08, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics , Inc. (Nasdaq: APRE ), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, today announced that Oren Gilad Ph.D, President and Chief

BOSTON , Aug. 11, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics , Inc. (Nasdaq: APRE ), a biopharmaceutical company focused on developing and commercializing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways today reported financial results for the three

BOSTON, Mass. , Aug. 02, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics , Inc. (Nasdaq: APRE ), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics targeting DNA damage response pathways, today announced that Oren Gilad Ph.D, President and Chief Executive

BOSTON , May 16, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics , Inc. (Nasdaq: APRE ), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics targeting DNA damage response pathways today announced that it has acquired Atrin Pharmaceuticals Inc.

BOSTON , March 15, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics , Inc. (Nasdaq: APRE ), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today reported financial results for the three months and

BOSTON , Jan. 06, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics , Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today announced that Christian S.

BOSTON , Dec. 14, 2021 (GLOBE NEWSWIRE) -- Lead investigators from clinical trials evaluating eprenetapopt in patients with  TP53  mutant MDS or AML presented positive, updated data at the 2021 ASH Annual Meeting. All studies evaluated the tolerability and efficacy of  Aprea Therapeutics, Inc.